LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.

Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.

Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.

The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.

As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.

But camizestrant’s use could depend on uptake of monitoring – for now.

In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.

Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.